Compass Pathways Plc

Research Compass Pathways Plc (CMPS) on Bullrun: market cap USD 2.03B. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCMPS
• ExchangeNASDAQ
• CountryUnited Kingdom
• SectorHealthcare
• IndustryMedical Care Facilities
• CurrencyUSD
• Market capUSD 2.03B
• Financial periodFY2025
• Net income-USD 269.77M

Valuation Snapshot

latest market cap is USD 2.03B.

About Compass Pathways Plc

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression; and is in Phase II clinical trial for treating post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020.

Frequently asked questions

What is Compass Pathways Plc's market cap?

Compass Pathways Plc's market capitalization is USD 2.03B.

What does Compass Pathways Plc do?

COMPASS Pathways plc operates as a biotechnology company that focuses on mental health in the United Kingdom and the United States. The company develops COMP360, a psilocybin therapy, which is in Phase III clinical trial for the treatment of treatment-resistant depression;